(Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
Date: |
2022 |
Abstract: |
Objectives: We assessed the prevalence of anti-hepatitis C virus (HCV) antibodies and active HCV infection (HCV-RNA-positive) in people living with HIV (PLWH) in Spain in 2019 and compared the results with those of four similar studies performed during 2015-2018. Methods: The study was performed in 41 centres. Sample size was estimated for an accuracy of 1%. Patients were selected by random sampling with proportional allocation. Results: The reference population comprised 41 973 PLWH, and the sample size was 1325. HCV serostatus was known in 1316 PLWH (99. 3%), of whom 376 (28. 6%) were HCV antibody (Ab)-positive (78. 7% were prior injection drug users); 29 were HCV-RNA-positive (2. 2%). Of the 29 HCV-RNA-positive PLWH, infection was chronic in 24, it was acute/recent in one, and it was of unknown duration in four. Cirrhosis was present in 71 (5. 4%) PLWH overall, three (10. 3%) HCV-RNA-positive patients and 68 (23. 4%) of those who cleared HCV after anti-HCV therapy (p = 0. 04). The prevalence of anti-HCV antibodies decreased steadily from 37. 7% in 2015 to 28. 6% in 2019 (p < 0. 001); the prevalence of active HCV infection decreased from 22. 1% in 2015 to 2. 2% in 2019 (p < 0. 001). Uptake of anti-HCV treatment increased from 53. 9% in 2015 to 95. 0% in 2019 (p < 0. 001). Conclusions: In Spain, the prevalence of active HCV infection among PLWH at the end of 2019 was 2. 2%, i. e. 90. 0% lower than in 2015. Increased exposure to DAAs was probably the main reason for this sharp reduction. Despite the high coverage of treatment with direct-acting antiviral agents, HCV-related cirrhosis remains significant in this population. |
Grants: |
Instituto de Salud Carlos III RD16/0025/0017 Instituto de Salud Carlos III RD16/0025/0018
|
Note: |
Altres ajuts: Spanish AIDS Research Network; European Funding for Regional Development (FEDER). |
Rights: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. |
Language: |
Anglès |
Document: |
Article ; recerca ; Versió publicada |
Subject: |
Coinfection/epidemiology ;
Hepatitis C/drug therapy/epidemiology ;
HIV infection/epidemiology |
Published in: |
HIV Medicine, Vol. 23 Núm. 7 (august 2022) , p. 705-716, ISSN 1468-1293 |